Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
Delayed Quote. Delayed Nasdaq - 01/26 04:00:00 pm
17.79 USD   -3.21%
01/21Health Care Stocks Retreat This Afternoon
MT
01/21Health Care Stocks Drifting Lower in Friday Trade
MT
01/21CureVac Shares Drop After BofA Securities Downgrade
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
21.85(c) 18.73(c) 18.22(c) 18.38(c) 17.79(c) Last
665 995 1 912 075 1 392 479 798 502 1 178 949 Volume
-2.76% -14.28% -2.72% +0.88% -3.21% Change
More quotes
Estimated financial data (e)
Sales 2021 61,8 M 69,2 M 69,2 M
Net income 2021 -521 M -584 M -584 M
Net cash position 2021 976 M 1 093 M 1 093 M
P/E ratio 2021 -5,48x
Yield 2021 -
Sales 2022 70,4 M 78,9 M 78,9 M
Net income 2022 -269 M -301 M -301 M
Net cash position 2022 665 M 744 M 744 M
P/E ratio 2022 -11,4x
Yield 2022 -
Capitalization 3 117 M 3 503 M 3 491 M
EV / Sales 2021 34,6x
EV / Sales 2022 34,8x
Nbr of Employees 505
Free-Float 44,9%
More Financials
Company
CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies. 
More about the company
Ratings of CureVac N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CUREVAC N.V.
01/21Health Care Stocks Retreat This Afternoon
MT
01/21Health Care Stocks Drifting Lower in Friday Trade
MT
01/21CureVac Shares Drop After BofA Securities Downgrade
MT
01/21BofA Securities Downgrades CureVac to Underperform From Neutral, Adjusts Price Target t..
MT
01/18CUREVAC N : Chief Technology Officer to Pursue New Career outside Biotech Industry - Form ..
PU
01/18JMP Securities Starts CureVac at Market Outperform With $52 Price Target
MT
01/18CureVac Technology Chief Mariola Fotin-Mleczek to Step Down
MT
01/17CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
EQ
01/17CureVac Announces Resignation of Mariola Fotin-Mleczek as Chief Technology Officer
CI
01/13CUREVAC N : In relation to the Parties' share portfolios in CureVac N.V. (NL-Amsterdam) - ..
PU
01/03CUREVAC N : Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as..
PU
2021CureVac Stock Slips Following Kempen's Stock Rating Downgrade
MT
2021Kempen Downgrades CureVac to Sell From Neutral, Adjusts Price Target to $20 From $50
MT
2021CUREVAC N.V.(NASDAQGM : CVAC) added to NASDAQ Biotechnology Index
CI
2021CUREVAC N : Interim Condensed Consolidated Statements of Operations and Other Comprehensiv..
PU
More news
News in other languages on CUREVAC N.V.
01/22Dpa-AFX Presseschau für das Wochenende - 1. Aktualisierung
01/21Les actions du secteur de la santé en baisse dans les échanges de vendredi
01/21Les actions de CureVac chutent après la rétrogradation de BofA Securities
01/21AKTIEN NEW YORK AUSBLICK : Talfahrt geht weiter - Netflix-Ausblick schockt
01/21Curevac mit weiterem Rekordtief - Bofa macht wenig Hoffnung
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 15,83 €
Average target price 38,45 €
Spread / Average Target 143%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean StÚphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-48.15%3 503
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601